Delcath Systems’ (DCTH) Buy Rating Reiterated at HC Wainwright

Delcath Systems (NASDAQ:DCTH)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $22.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 115.05% from the company’s current price.

A number of other equities research analysts have also recently weighed in on the company. StockNews.com cut Delcath Systems from a “hold” rating to a “sell” rating in a research note on Thursday. Craig Hallum initiated coverage on Delcath Systems in a research note on Friday, June 28th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Stephens restated an “overweight” rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Tuesday, August 6th.

Delcath Systems Stock Up 7.6 %

Shares of Delcath Systems stock opened at $10.23 on Friday. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $11.74. The stock has a market cap of $284.25 million, a P/E ratio of -3.86 and a beta of 0.78. The business’s 50 day moving average is $9.05 and its 200-day moving average is $7.66.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. The company had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. During the same quarter in the prior year, the company earned ($0.58) EPS. On average, sell-side analysts expect that Delcath Systems will post -1.67 EPS for the current year.

Institutional Trading of Delcath Systems

Several large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new stake in shares of Delcath Systems during the 2nd quarter worth $370,000. Shellback Capital LP bought a new position in Delcath Systems in the second quarter valued at about $1,353,000. Marshall Wace LLP raised its position in Delcath Systems by 7.0% in the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock valued at $776,000 after purchasing an additional 6,066 shares during the last quarter. Renaissance Technologies LLC bought a new position in Delcath Systems in the second quarter valued at about $694,000. Finally, AIGH Capital Management LLC raised its position in Delcath Systems by 1.7% in the second quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock valued at $20,086,000 after purchasing an additional 40,064 shares during the last quarter. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.